Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition.

Kodela R, Chattopadhyay M, Goswami S, Gan ZY, Rao PP, Nia KV, Velázquez-Martínez CA, Kashfi K.

J Pharmacol Exp Ther. 2013 Apr;345(1):85-94. doi: 10.1124/jpet.112.201970. Epub 2013 Jan 24.

2.

Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling.

Vannini F, Chattopadhyay M, Kodela R, Rao PP, Kashfi K.

Redox Biol. 2015 Dec;6:318-25. doi: 10.1016/j.redox.2015.08.014. Epub 2015 Aug 20.

3.
4.

NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.

Chattopadhyay M, Kodela R, Olson KR, Kashfi K.

Biochem Biophys Res Commun. 2012 Mar 16;419(3):523-8. doi: 10.1016/j.bbrc.2012.02.051. Epub 2012 Feb 16.

PMID:
22366248
5.

Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo.

Kashfi K, Borgo S, Williams JL, Chen J, Gao J, Glekas A, Benedini F, Del Soldato P, Rigas B.

J Pharmacol Exp Ther. 2005 Mar;312(3):978-88. Epub 2004 Nov 4.

6.

Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor.

Brzozowska I, Targosz A, Sliwowski Z, Kwiecien S, Drozdowicz D, Pajdo R, Konturek PC, Brzozowski T, Pawlik M, Konturek SJ, Pawlik WW, Hahn EG.

J Physiol Pharmacol. 2004 Dec;55(4):773-90.

7.

Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect.

Zhao W, Mackenzie GG, Murray OT, Zhang Z, Rigas B.

Carcinogenesis. 2009 Mar;30(3):512-9. doi: 10.1093/carcin/bgp015. Epub 2009 Jan 9.

9.

Activation of genes for spasmolytic peptide, transforming growth factor alpha and for cyclooxygenase (COX)-1 and COX-2 during gastric adaptation to aspirin damage in rats.

Konturek PC, Brzozowski T, Pierzchalski P, Kwiecien S, Pajdo R, Hahn EG, Konturek SJ.

Aliment Pharmacol Ther. 1998 Aug;12(8):767-77.

11.

Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma.

Bak AW, McKnight W, Li P, Del Soldato P, Calignano A, Cirino G, Wallace JL.

Life Sci. 1998;62(23):PL 367-73.

PMID:
9627095
12.

Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo.

Nath N, Chattopadhyay M, Rodes DB, Nazarenko A, Kodela R, Kashfi K.

Molecules. 2015 Jul 9;20(7):12481-99. doi: 10.3390/molecules200712481.

14.

Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators.

Kalgutkar AS, Kozak KR, Crews BC, Hochgesang GP Jr, Marnett LJ.

J Med Chem. 1998 Nov 19;41(24):4800-18.

PMID:
9822550
15.
16.

Gastroprotective and ulcer healing effects of nitric oxide-releasing non-steroidal anti-inflammatory drugs.

Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Drozdowicz D, Kwiecień S, Pajdo R, Ptak A, Pawlik M, Hahn E.

Dig Liver Dis. 2000 Oct;32(7):583-94.

PMID:
11142556
17.

Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells.

Gao J, Niwa K, Sun W, Takemura M, Lian Z, Onogi K, Seishima M, Mori H, Tamaya T.

Cancer Sci. 2004 Nov;95(11):901-7.

18.

COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.

Grösch S, Tegeder I, Niederberger E, Bräutigam L, Geisslinger G.

FASEB J. 2001 Dec;15(14):2742-4. Epub 2001 Oct 15.

PMID:
11606477
20.

Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs.

Chattopadhyay M, Velazquez CA, Pruski A, Nia KV, Abdellatif KR, Keefer LK, Kashfi K.

J Pharmacol Exp Ther. 2010 Nov;335(2):443-50. doi: 10.1124/jpet.110.171017. Epub 2010 Aug 2. Erratum in: J Pharmacol Exp Ther. 2010 Dec;335(3):861.

Supplemental Content

Support Center